The utility of high-mobility group A2 overexpression for predicting the prognosis of gastric cancer patients and its contribution to poor prognosis via chemoresistance and the propensity for the occurrence of carcinomatosis peritonei

Lee, Hayemin; Lee, Han Hong; Lim, Chae Youn; Lee, Junhyun

doi:10.1016/j.surg.2020.11.020

Cited by 1 publication

(1 citation statement)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…High expression of HMGA1 has already been correlated with worse survival in GC patients but only in studies that used series with a relatively small number of cases [ 28 , 43 ] or TCGA/GEPIA datasets [ 17 , 27 ]. High expression of another member of the family, HMGA2, has also been reported as predicting bad prognoses in two series of Asian GC patients [ 43 , 48 ]. However, in our series, we did not observe a prognostic value for HMGA1.…”

Section: Discussionmentioning

confidence: 99%

HMGA1 Has Predictive Value in Response to Chemotherapy in Gastric Cancer

et al. 2021

View full text Add to dashboard Cite

Gastric cancer is a serious health problem worldwide. Although its incidence is decreasing, the five-year survival rate remains low. Thus, it is essential to identify new biomarkers that could promote better diagnosis and treatment of patients with gastric cancer. High-mobility group AT-hook 1 (HMGA1) is a non-histone, chromatin-binding protein that has been found overexpressed in several tumor types. It has been correlated with invasion, metastasis, and drug resistance, leading to worse patient survival. The aim of this work was to evaluate the clinical value of HMGA1 in gastric cancer. HMGA1 expression was analyzed by immunohistochemistry in a single hospital series (n = 323) of gastric adenocarcinoma cases (stages I to IV) with clinicopathological and treatment data. In this series, HMGA1 expression showed no significant relevance as a prognostic biomarker. Nevertheless, a significantly better overall survival was observed in cases with high levels of HMGA1 when they were treated with chemotherapy, compared to the nontreated ones, implying that they can benefit more from treatment than patients with low expression of HMGA1. We thereby show for the first time that HMGA1 expression has a substantial value as a biomarker of response to chemotherapy in gastric cancer.

show abstract